Nasdaq · CIK 0001384101
VCYT VERACYTE, INC.
Insider trading from SEC Form 4. Last filing 20 d ago. Close $45.23 on Oct 9, 2026, +51% from the 52-week low and -25% from the high.
Last 90 days
Net insider value
-$1.3M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
6
$1.3M by 6 insiders
Insiders on file
14
with a Form 4 at this company
Price and insider trades, last year
VCYTOct 9, 2026 · close 45.23
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at VERACYTE, INC., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 14Weak | John Leite Global Chief Commercial Off sell | $161k 4,015 shares | -3% | - | |
| 27Weak | Jens Holstein director sell | $205k 5,000 shares | -15% | +37% from low-32% from high | |
| 28Weak | Rebecca Chambers Chief Financial Officer sell | $157k 3,652 shares | -2% | +42% from low-30% from high | |
| 29Weak | Phillip G. Febbo Chief Scientific & Med Officer sell | $564k 13,110 shares | -9% | +42% from low-30% from high | |
| 21Weak | Annie McGuire EVP, General Counsel sell | $140k 3,254 shares | -2% | +42% from low-30% from high | |
| 19Weak | Muna Bhanji director sell | $80k 1,864 shares | -4% | +45% from low-28% from high | |
| 25Weak | Muna Bhanji director sell | $122k 4,589 shares | -13% | 0% from low-43% from high | |
| 25Weak | Karin Eastham director sell | $122k 4,590 shares | -25% | 0% from low-43% from high | |
| 18Weak | John Leite Chief Commercial Officer-CLIA sell | $76k 2,809 shares | -3% | +3% from low-41% from high | |
| 8Weak | Phillip G. Febbo Chief Scientific & Med Officer sell | $268k 8,037 shares | -9% | - | |
| 2Weak | Rebecca Chambers Chief Financial Officer sell | $23k 527 shares | -0% | - | |
| 6Weak | Karin Eastham director sell | $403k 10,000 shares | -35% | - | |
| 33Weak | Marc Stapley Chief Executive Officer sell | $243k 5,590 shares | -2% | - | |
| 21Weak | Phillip G. Febbo Chief Scientific & Med Officer sell | $173k 3,934 shares | -5% | - | |
| 38Weak | Annie McGuire SVP, General Counsel sell | $823k 18,699 shares | -20% | - | |
| 31Weak | Rebecca Chambers Chief Financial Officer sell | $303k 7,000 shares | -6% | - | |
| 16Weak | John Leite Chief Commercial Officer-CLIA sell | $45k 1,050 shares | -1% | - | |
| 36Weak | Jonathan Wygant VP, Chief Accounting Officer sell | $41k 956 shares | -2% | - | |
| 47Moderate | Jonathan Wygant VP, Chief Accounting Officer sell | $216k 5,032 shares | -11% | - | |
| 39Weak | Karin Eastham director sell | $565k 14,731 shares | -44% | - | |
| 41Moderate | Rebecca Chambers Chief Financial Officer sell | $586k 15,275 shares | -11% | - | |
| 24Weak | Robert S Epstein director sell | $575k 15,000 shares | -25% | - |
Congressional trades
3 trades in VCYT disclosed by members of Congress under the STOCK Act. All congressional trades.
- Gilbert Ray Cisneros, Jr.House · D-CA · last Apr 7, 20262 bought
1 sold
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | VCYT Veracyte, Inc. - Common Stock | $1,001 to $15k | Mar 3 / Apr 7 35 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Partial sale | VCYT Veracyte, Inc. - Common Stock | $1,001 to $15k | Nov 12, 2025 / Dec 15, 2025 33 days after the trade | Clerk |
Gilbert Ray Cisneros, Jr. House · D-CA | Purchase | VCYT Veracyte, Inc. - Common Stock | $1,001 to $15k | Jun 16, 2025 / Jul 10, 2025 24 days after the trade | Clerk |
Transactions
The last 72 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | John Leite Global Chief Commercial Off | SOpen-market sale Common Stock10b5-1 | -4,015 | $40.00 | $161k | 124,329 | 20 d ago |
| Sep 14, 2026 | Jens Holstein director | SOpen-market sale Common Stock10b5-1 | -5,000 | $40.95 | $205k | 27,471 | 26 d ago |
| Sep 2, 2026 | Jonathan Wygant VP, Chief Accounting Officer | FTax withholding Common Stock | -1,361 | $44.88 | $61k | 43,226 | 38 d ago |
| Sep 2, 2026 | Marc Stapley Chief Executive Officer | FTax withholding Common Stock | -8,782 | $44.88 | $394k | 432,073 | 38 d ago |
| Sep 2, 2026 | Rebecca Chambers Chief Financial Officer | FTax withholding Common Stock10b5-1 | -3,603 | $44.88 | $162k | 169,677 | 38 d ago |
| Sep 2, 2026 | Phillip G. Febbo Chief Scientific & Med Officer | FTax withholding Common Stock10b5-1 | -3,639 | $44.88 | $163k | 146,158 | 38 d ago |
| Sep 2, 2026 | John Leite Global Chief Commercial Off | FTax withholding Common Stock | -3,961 | $44.88 | $178k | 128,344 | 38 d ago |
| Sep 2, 2026 | Annie McGuire EVP, General Counsel | FTax withholding Common Stock10b5-1 | -3,215 | $44.88 | $144k | 134,414 | 38 d ago |
| Sep 4, 2026 | Rebecca Chambers Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -2,477 | $42.81 | $106k | 167,200 | 38 d ago |
| Sep 4, 2026 | Phillip G. Febbo Chief Scientific & Med Officer | SOpen-market sale Common Stock10b5-1 | -10,405 | $42.89 | $446k | 135,753 | 38 d ago |
| Sep 4, 2026 | Annie McGuire EVP, General Counsel | SOpen-market sale Common Stock10b5-1 | -2,154 | $42.79 | $92k | 132,260 | 38 d ago |
| Sep 4, 2026 | Rebecca Chambers Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -1,175 | $43.71 | $51k | 166,025 | 38 d ago |
| Sep 4, 2026 | Annie McGuire EVP, General Counsel | SOpen-market sale Common Stock10b5-1 | -1,100 | $43.67 | $48k | 131,160 | 38 d ago |
| Sep 4, 2026 | Phillip G. Febbo Chief Scientific & Med Officer | SOpen-market sale Common Stock10b5-1 | -2,705 | $43.66 | $118k | 133,048 | 38 d ago |
| Sep 1, 2026 | Muna Bhanji director | SOpen-market sale Common Stock10b5-1 | -1,864 | $42.97 | $80k | 42,718 | 39 d ago |
| Sep 2, 2025 | Rebecca Chambers Chief Financial Officer | FTax withholding Common Stock | -5,371 | $30.11 | $162k | 133,158 | Sep 4, 2025 |
| Sep 2, 2025 | Phillip G. Febbo Chief Scientific & Med Officer | FTax withholding Common Stock | -2,955 | $30.11 | $89k | 100,790 | Sep 4, 2025 |
| Jun 18, 2025 | David Brent Shafer director | AGrant or award Common Stock | +9,321 | $0.00 | $0 | 25,828 | Jun 23, 2025 |
| Jun 18, 2025 | Thomas F. Miller director | AGrant or award Common Stock | +9,321 | $0.00 | $0 | 25,828 | Jun 23, 2025 |
| Jun 18, 2025 | Karin Eastham director | AGrant or award Common Stock | +9,321 | $0.00 | $0 | 23,228 | Jun 23, 2025 |
| Jun 18, 2025 | Evan/ Fa Jones director | AGrant or award Common Stock | +9,321 | $0.00 | $0 | 43,664 | Jun 23, 2025 |
| Jun 18, 2025 | Jens Holstein director | AGrant or award Common Stock | +9,321 | $0.00 | $0 | 37,199 | Jun 23, 2025 |
| Jun 18, 2025 | Robert S Epstein director | AGrant or award Common Stock | +9,321 | $0.00 | $0 | 73,919 | Jun 23, 2025 |
| Jun 18, 2025 | Muna Bhanji director | AGrant or award Common Stock | +9,321 | $0.00 | $0 | 39,310 | Jun 23, 2025 |
| Jun 18, 2025 | Eliav Barr director | AGrant or award Common Stock | +9,321 | $0.00 | $0 | 51,189 | Jun 23, 2025 |
| Jun 13, 2025 | Muna Bhanji director | SOpen-market sale Common Stock10b5-1 | -4,589 | $26.67 | $122k | 29,989 | Jun 17, 2025 |
| Jun 13, 2025 | Karin Eastham director | SOpen-market sale Common Stock10b5-1 | -4,590 | $26.66 | $122k | 13,907 | Jun 17, 2025 |
| Jun 4, 2025 | John Leite Chief Commercial Officer-CLIA | SOpen-market sale Common Stock10b5-1 | -2,809 | $27.20 | $76k | 94,540 | Jun 6, 2025 |
| Jun 2, 2025 | Rebecca Chambers Chief Financial Officer | FTax withholding Common Stock | -5,370 | $26.74 | $144k | 138,529 | Jun 4, 2025 |
| Jun 2, 2025 | Phillip G. Febbo Chief Scientific & Med Officer | FTax withholding Common Stock | -2,955 | $26.74 | $79k | 103,745 | Jun 4, 2025 |
| Jun 2, 2025 | John Leite Chief Commercial Officer-CLIA | FTax withholding Common Stock | -2,900 | $26.74 | $78k | 97,349 | Jun 4, 2025 |
| Jun 2, 2025 | Annie McGuire SVP, General Counsel | FTax withholding Common Stock | -3,505 | $26.74 | $94k | 97,003 | Jun 4, 2025 |
| Jun 2, 2025 | Marc Stapley Chief Executive Officer | FTax withholding Common Stock | -9,399 | $26.74 | $251k | 349,237 | Jun 4, 2025 |
| Jun 2, 2025 | Jonathan Wygant VP, Chief Accounting Officer | FTax withholding Common Stock | -1,848 | $26.74 | $49k | 47,915 | Jun 4, 2025 |
| Mar 6, 2025 | Rebecca Chambers Chief Financial Officer | AGrant or award Common Stock | +30,200 | $0.00 | $0 | 143,899 | Mar 10, 2025 |
| Mar 6, 2025 | Phillip G. Febbo Chief Scientific & Med Officer | AGrant or award Common Stock | +24,160 | $0.00 | $0 | 106,700 | Mar 10, 2025 |
| Mar 4, 2025 | Phillip G. Febbo Chief Scientific & Med Officer | SOpen-market sale Common Stock10b5-1 | -4,467 | $32.86 | $147k | 86,110 | Mar 6, 2025 |
| Mar 4, 2025 | Phillip G. Febbo Chief Scientific & Med Officer | SOpen-market sale Common Stock10b5-1 | -3,570 | $33.95 | $121k | 82,540 | Mar 6, 2025 |
| Feb 27, 2025 | Rebecca Chambers Chief Financial Officer | AGrant or award Common Stock | +23,170 | $0.00 | $0 | 136,680 | Mar 3, 2025 |
| Feb 27, 2025 | Phillip G. Febbo Chief Scientific & Med Officer | AGrant or award Common Stock | +30,589 | $0.00 | $0 | 113,003 | Mar 3, 2025 |
| Feb 27, 2025 | Phillip G. Febbo Chief Scientific & Med Officer | FTax withholding Common Stock | -15,672 | $33.84 | $530k | 97,331 | Mar 3, 2025 |
| Feb 27, 2025 | Rebecca Chambers Chief Financial Officer | FTax withholding Common Stock | -11,911 | $33.84 | $403k | 124,769 | Mar 3, 2025 |
| Mar 2, 2025 | Rebecca Chambers Chief Financial Officer | FTax withholding Common Stock | -11,070 | $34.76 | $385k | 113,699 | Mar 3, 2025 |
| Mar 2, 2025 | Phillip G. Febbo Chief Scientific & Med Officer | FTax withholding Common Stock | -6,754 | $34.76 | $235k | 90,577 | Mar 3, 2025 |
| Feb 3, 2025 | Rebecca Chambers Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -527 | $43.85 | $23k | 113,510 | Feb 5, 2025 |
| Jan 6, 2025 | Robert S Epstein director | MOption exercise Common Stock | +20,000 | $8.04 | $161k | 64,598 | Jan 8, 2025 |
| Jan 6, 2025 | Robert S Epstein director | MOption exercise Stock Option (right to buy)derivative | -20,000 | $0.00 | $0 | 0 | Jan 8, 2025 |
| Jan 2, 2025 | Karin Eastham director | MOption exercise Common Stock10b5-1 | +10,000 | $5.28 | $53k | 28,497 | Jan 6, 2025 |
| Jan 2, 2025 | Karin Eastham director | SOpen-market sale Common Stock10b5-1 | -5,309 | $40.12 | $213k | 23,188 | Jan 6, 2025 |
| Jan 2, 2025 | Karin Eastham director | SOpen-market sale Common Stock10b5-1 | -4,691 | $40.50 | $190k | 18,497 | Jan 6, 2025 |
| Jan 2, 2025 | Karin Eastham director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -10,000 | $0.00 | $0 | 0 | Jan 6, 2025 |
| Dec 13, 2024 | Marc Stapley Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -5,190 | $43.37 | $225k | 307,745 | Dec 17, 2024 |
| Dec 13, 2024 | Marc Stapley Chief Executive Officer | SOpen-market sale Common Stock10b5-1 | -400 | $44.14 | $18k | 307,345 | Dec 17, 2024 |
| Dec 4, 2024 | Annie McGuire SVP, General Counsel | SOpen-market sale Common Stock10b5-1 | -18,699 | $44.02 | $823k | 72,869 | Dec 6, 2024 |
| Dec 4, 2024 | Phillip G. Febbo Chief Scientific & Med Officer | SOpen-market sale Common Stock10b5-1 | -3,934 | $44.09 | $173k | 82,414 | Dec 6, 2024 |
| Dec 2, 2024 | Jonathan Wygant VP, Chief Accounting Officer | FTax withholding Common Stock | -1,087 | $44.12 | $48k | 41,226 | Dec 4, 2024 |
| Dec 2, 2024 | Marc Stapley Chief Executive Officer | FTax withholding Common Stock | -5,748 | $44.12 | $254k | 312,935 | Dec 4, 2024 |
| Dec 2, 2024 | Rebecca Chambers Chief Financial Officer | FTax withholding Common Stock10b5-1 | -3,464 | $44.12 | $153k | 121,037 | Dec 4, 2024 |
| Dec 2, 2024 | Phillip G. Febbo Chief Scientific & Med Officer | FTax withholding Common Stock | -6,738 | $44.12 | $297k | 86,348 | Dec 4, 2024 |
| Dec 2, 2024 | John Leite Chief Commercial Officer-CLIA | FTax withholding Common Stock | -1,314 | $44.12 | $58k | 74,860 | Dec 4, 2024 |
| Dec 2, 2024 | Annie McGuire SVP, General Counsel | FTax withholding Common Stock | -1,918 | $44.12 | $85k | 91,568 | Dec 4, 2024 |
| Dec 3, 2024 | Rebecca Chambers Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -7,000 | $43.23 | $303k | 114,037 | Dec 4, 2024 |
| Dec 3, 2024 | Jonathan Wygant VP, Chief Accounting Officer | SOpen-market sale Common Stock | -956 | $43.36 | $41k | 40,270 | Dec 4, 2024 |
| Dec 3, 2024 | John Leite Chief Commercial Officer-CLIA | SOpen-market sale Common Stock10b5-1 | -1,050 | $43.25 | $45k | 73,810 | Dec 4, 2024 |
| Nov 27, 2024 | Jonathan Wygant VP, Chief Accounting Officer | SOpen-market sale Common Stock | -5,032 | $42.89 | $216k | 42,313 | Nov 29, 2024 |
| Nov 19, 2024 | Karin Eastham director | SOpen-market sale Common Stock10b5-1 | -1,600 | $36.77 | $59k | 31,628 | Nov 21, 2024 |
| Nov 19, 2024 | Karin Eastham director | SOpen-market sale Common Stock10b5-1 | -3,006 | $37.77 | $114k | 28,622 | Nov 21, 2024 |
| Nov 19, 2024 | Karin Eastham director | SOpen-market sale Common Stock10b5-1 | -10,125 | $38.76 | $392k | 18,497 | Nov 21, 2024 |
| Nov 12, 2024 | Rebecca Chambers Chief Financial Officer | SOpen-market sale Common Stock10b5-1 | -15,275 | $38.34 | $586k | 124,501 | Nov 14, 2024 |
| Nov 12, 2024 | Robert S Epstein director | MOption exercise Common Stock10b5-1 | +15,000 | $8.04 | $121k | 59,598 | Nov 14, 2024 |
| Nov 12, 2024 | Robert S Epstein director | SOpen-market sale Common Stock10b5-1 | -15,000 | $38.32 | $575k | 44,598 | Nov 14, 2024 |
| Nov 12, 2024 | Robert S Epstein director | MOption exercise Stock Option (right to buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 20,000 | Nov 14, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Eliav Barrdirector
- Muna Bhanjidirector
- Rebecca ChambersChief Financial Officer
- Karin Easthamdirector
- Robert S Epsteindirector
- Phillip G. FebboChief Scientific & Med Officer
- Jens Holsteindirector
- Evan/ Fa Jonesdirector
- John LeiteChief Commercial Officer-CLIA
- Annie McGuireSVP, General Counsel
- Thomas F. Millerdirector
- David Brent Shaferceo, chair, officer, director, other
- Marc StapleyChief Executive Officer
- Jonathan WygantVP, Chief Accounting Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.